| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25041 |
| Drug |
Acalabrutinib |
| Brand |
Calquence® |
| Indication |
Acalabrutinib (Calquence®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT). |
| Rapid review commissioned |
30/06/2025 |
| Rapid review completed |
21/07/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of acalabrutinib in combination with bendamustine and rituximab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/07/2025 |
| Pre-submission consultation with Applicant |
11/09/2025 |
